Dissection of Pharmacological Mechanism of Chinese Herbal Medicine Yihuo Huatan Formula on Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study

被引:0
作者
Xia-Wei Zhang
Wei Liu
Hong-Li Jiang
Bing Mao
机构
[1] Sichuan University,Division of Respiratory Medicine, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital
[2] Sichuan University,Division of Pulmonary Diseases, State Key Laboratory of Biotherapy, West China Hospital, West China School of Medicine
来源
Scientific Reports | / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases. Yihuo Huatan Formula (YHF), as a proven Chinese Herbal Medicine (CHM), has been verified to be effective in the treatment of stable COPD through years’ of practice. Nevertheless, its working mechanism is still unclear. We sought to systematically decipher the mechanism of YHF for treating stable COPD using systems pharmacology-based method that integrates pharmacokinetic screening, target prediction, network analyses, GO and KEGG enrichment analyses. Firstly, a total of 1267 chemicals out of 15 herbal components were included in YHF chemical database. Among them, 180 potential active molecules were screened out through pharmacokinetic evaluation. Then 258 targets of the active molecules were predicted, of which 84 were chosen for further analyses. Finally, the network analyses and GO and KEGG enrichment methods suggested a therapeutic effect of YHF on the alleviation of airway inflammation, decrease of mucus secretion, maintenance of immune homeostasis and benefit of COPD comorbidities, by regulating multiple targets and pathways. The systems pharmacology-based approach helps to understand the underlying working mechanism of YHF in stable COPD from a holistic perspective, and offers an exemplification for systematically uncovering the action mechanisms of CHM.
引用
收藏
相关论文
共 100 条
  • [1] Zhong N(2007)Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey Am. J. Respir. Crit. Care Med. 176 753-760
  • [2] Wang C(2018)Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study Lancet 391 1706-1717
  • [3] Rogliani P(2019)Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease Expert Opin. Pharmacother. 20 737-750
  • [4] Salpeter SR(2004)Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis Chest 125 2309-2321
  • [5] Ormiston TM(2008)Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis Jama 300 1439-1450
  • [6] Salpeter EE(2013)Inhaled corticosteroids in COPD and the risk of serious pneumonia Thorax 68 1029-1036
  • [7] Singh S(2007)Mucolytics, expectorants, and mucokinetic medications Respir. Care 52 859-865
  • [8] Loke YK(2012)Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study BMC Complement. Altern. Med. 12 197-2488
  • [9] Furberg CD(2016)Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage Exp. Ther. Med. 12 2477-733
  • [10] Suissa S(2015)Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease Sci. Rep. 5 9146378-86